BMO Capital Cuts Price Target On HCA Healthcare

BMO Capital has lowered the price target on HCA Healthcare Inc HCA to $250 from $275 while keeping the Market Perform rating on the shares after its Q4 results. 

• Analyst Matt Borsch notes execution was very strong, but HCA still contends with near-term issues that include uneven volumes, staffing constraints, and related wage and other inflation.
• The analyst also adds that the Q4 results are likely to continue to be volatile.
• Related: HCA Healthcare Q4 Earnings Lag Estimates, Issues FY22 Guidance.
• After the earnings, Cowen lowered the price target from $302 to $265 and kept an Outperform rating on the shares. 
• The analyst updated his model by slightly lowering its EBITDA for 2022, 2023, and 2024 due to COVID costs/occupancy and deferred surgical recovery labor costs.
• Price Action: HCA shares are up 1.55% at $240.26 during the market session on the last check Monday.